Total Payments
$869,405
2024 Payments
$23,670
Companies
35
Transactions
561
Medicare Patients
5,171
Medicare Billing
$218,391
Payment Breakdown by Category
Consulting$577,966 (66.5%)
Research$125,476 (14.4%)
Other$118,050 (13.6%)
Travel$44,235 (5.1%)
Food & Beverage$3,629 (0.4%)
Education$48.93 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $577,966 | 167 | 66.5% |
| Unspecified | $125,476 | 199 | 14.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $107,450 | 41 | 12.4% |
| Travel and Lodging | $44,235 | 74 | 5.1% |
| Grant | $8,100 | 2 | 0.9% |
| Food and Beverage | $3,629 | 67 | 0.4% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $2,500 | 1 | 0.3% |
| Education | $48.93 | 10 | 0.0% |
Payments by Type
General
$743,929
362 transactions
Research
$125,476
199 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $136,688 | 77 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $102,275 | 45 | $0 (2021) |
| Boehringer Ingelheim Limited | $97,117 | 4 | $0 (2017) |
| Boehringer Ingelheim International GmbH | $77,284 | 44 | $0 (2024) |
| PFIZER INC. | $75,862 | 63 | $0 (2024) |
| Janssen Research & Development, LLC | $67,933 | 30 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $66,510 | 30 | $0 (2021) |
| SANOFI US SERVICES INC. | $44,406 | 116 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $30,922 | 21 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $27,858 | 25 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,670 | 9 | PFIZER INC. ($10,200) |
| 2023 | $29,447 | 13 | Janssen Global Services, LLC ($8,220) |
| 2022 | $79,619 | 42 | PFIZER INC. ($29,110) |
| 2021 | $88,171 | 56 | Amgen Inc. ($28,791) |
| 2020 | $114,493 | 49 | Merck Sharp & Dohme Corporation ($32,725) |
| 2019 | $151,482 | 110 | SANOFI US SERVICES INC. ($35,574) |
| 2018 | $136,609 | 186 | Amgen Inc. ($32,694) |
| 2017 | $245,914 | 96 | Boehringer Ingelheim Limited ($97,117) |
All Payment Transactions
561 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,131.00 | General |
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,725.00 | General |
| 11/13/2024 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,040.00 | General |
| Category: DIABETES | ||||||
| 07/02/2024 | PFIZER INC. | STEGLATRO (Drug) | — | In-kind items and services | $1,900.00 | Research |
| Study: ERTUGLIFLOZIN CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 07/02/2024 | PFIZER INC. | STEGLATRO (Drug) | — | In-kind items and services | $1,900.00 | Research |
| Study: ERTUGLIFLOZIN CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 06/19/2024 | Chiesi USA, Inc. | JUXTAPID (Drug) | — | Cash or cash equivalent | $1,050.00 | Research |
| Study: LOWER:LomitapideObservational Worldwide Evaluation Registry (LOWER) • Category: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ||||||
| 06/13/2024 | PFIZER INC. | STEGLATRO (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ERTUGLIFLOZIN CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 06/05/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $4,524.00 | General |
| 05/23/2024 | PFIZER INC. | STEGLATRO (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ERTUGLIFLOZIN CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 12/18/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $8,100.00 | General |
| 11/20/2023 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| 11/09/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 07/06/2023 | Amryt Pharma Holdings Ltd | Juxtapid (Drug) | — | Cash or cash equivalent | $1,050.00 | Research |
| Study: LOWER: Lomitapide Observational Worldwide Evaluation Registry • Category: Cardiology/Vascular Diseases | ||||||
| 06/20/2023 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $1,740.00 | General |
| 06/13/2023 | CSL Behring | — | Consulting Fee | Cash or cash equivalent | $2,245.00 | General |
| 06/13/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 03/24/2023 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,305.00 | General |
| Category: DIABETES | ||||||
| 02/23/2023 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $26.69 | General |
| Category: Heart Failure and Hypertension | ||||||
| 01/21/2023 | PFIZER INC. | STEGLATRO (Drug) | — | In-kind items and services | $1,900.00 | Research |
| Study: ERTUGLIFLOZIN CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 01/19/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | LEQVIO (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/19/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 01/12/2023 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $2,880.00 | General |
| 12/19/2022 | PFIZER INC. | STEGLATRO (Drug) | — | In-kind items and services | $1,900.00 | Research |
| Study: ERTUGLIFLOZIN CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 11/23/2022 | PFIZER INC. | STEGLATRO (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: ERTUGLIFLOZIN CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 11/16/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $6,825.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ERTUGLIFLOZIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $70,450 | 59 |
| PRALUENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $24,353 | 15 |
| LOWER: Lomitapide Observational Worldwide Evaluation Registry | Amryt Pharma Holdings Ltd | $10,250 | 4 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi | SANOFI US SERVICES INC. | $8,200 | 110 |
| GOULD | Amgen Inc. | $7,049 | 3 |
| A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553REGN727 Versus Ezetimibe in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy | Regeneron Pharmaceuticals, Inc. | $2,527 | 1 |
| HEALTH ECONOMICS OUTCOME RESEARCH RELATED TO PRALUENT | Regeneron Pharmaceuticals, Inc. | $1,295 | 3 |
| LOWER:LomitapideObservational Worldwide Evaluation Registry (LOWER) | Chiesi USA, Inc. | $1,050 | 1 |
| Primary 2-Year Results of GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Diseas | Amgen Inc. | $157.77 | 1 |
| (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States | Amgen Inc. | $73.33 | 1 |
| Use of guideline-recommended risk-reduction strategies among patients with Type 2 diabetes and estab | Amgen Inc. | $71.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,472 | 1,815 | $357,109 | $68,996 |
| 2022 | 11 | 1,292 | 1,692 | $298,777 | $61,298 |
| 2021 | 11 | 1,321 | 1,656 | $252,311 | $54,023 |
| 2020 | 12 | 1,086 | 1,331 | $163,986 | $34,075 |
Total Patients
5,171
Total Services
6,494
Medicare Billing
$218,391
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 179 | 211 | $103,683 | $19,854 | 19.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 66 | 71 | $52,765 | $10,310 | 19.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 41 | 93 | $40,875 | $9,370 | 22.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 874 | 1,086 | $36,958 | $7,271 | 19.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 50 | 50 | $38,148 | $6,388 | 16.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 36 | 77 | $23,290 | $5,158 | 22.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 26 | 26 | $20,930 | $3,818 | 18.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 37 | 37 | $11,320 | $2,486 | 22.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 28 | 28 | $11,284 | $1,732 | 15.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 12 | 13 | $6,919 | $1,211 | 17.5% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 41 | 41 | $3,635 | $681.05 | 18.7% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 41 | 41 | $5,908 | $457.86 | 7.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 41 | 41 | $1,394 | $260.68 | 18.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 67 | 164 | $67,126 | $14,218 | 21.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 114 | 140 | $55,685 | $10,994 | 19.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 49 | 121 | $34,320 | $7,386 | 21.5% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 816 | 1,002 | $34,813 | $6,925 | 19.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 64 | 79 | $31,452 | $6,362 | 20.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 35 | $27,727 | $5,743 | 20.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 22 | 22 | $12,190 | $2,522 | 20.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 22 | 26 | $10,352 | $2,071 | 20.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 14 | 14 | $8,194 | $1,638 | 20.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 21 | 21 | $6,083 | $1,302 | 21.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 14 | 14 | $5,922 | $1,271 | 21.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 13 | 13 | $3,490 | $620.01 | 17.8% |
About Dr. Christopher Cannon, MD
Dr. Christopher Cannon, MD is a Cardiovascular Disease healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548227960.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Cannon, MD has received a total of $869,405 in payments from pharmaceutical and medical device companies, with $23,670 received in 2024. These payments were reported across 561 transactions from 35 companies. The most common payment nature is "Consulting Fee" ($577,966).
As a Medicare-enrolled provider, Cannon has provided services to 5,171 Medicare beneficiaries, totaling 6,494 services with total Medicare billing of $218,391. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Boston, MA
- Active Since 04/28/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1548227960
Products in Payments
- Repatha (Biological) $128,844
- STEGLATRO (Drug) $97,483
- PRADAXA (Drug) $94,274
- PRALUENT (Drug) $77,687
- SOTAGLIFLOZIN (Drug) $36,829
- JARDIANCE (Drug) $24,288
- PRALUENT ALIROCUMAB INJECTION (Biological) $18,916
- PLAVIX (Drug) $14,601
- PRALUENT (Biological) $12,006
- Juxtapid (Drug) $10,250
- MK-0859 (Drug) $9,878
- SAR439954 (Drug) $8,200
- ELIQUIS (Drug) $7,978
- NO PRODUCT DISCUSSED (Drug) $7,584
- XARELTO (Drug) $7,501
- Vascepa (Drug) $7,410
- LEQVIO (Drug) $6,060
- Belviq (Drug) $5,106
- PRAXBIND (Drug) $2,526
- Kerendia (Drug) $2,250
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Boston
Dr. Elizabeth Nabel, M.d, M.D
Cardiovascular Disease — Payments: $3.0M
Cardiovascular Disease $3.0M
Kenneth Rosenfield, M.d, M.D
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Dr. Eric Secemsky, Md, Msc, MD, MSC
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Dr. Benjamin Scirica, M.d, M.D
Cardiovascular Disease — Payments: $1.0M
Cardiovascular Disease $1.0M
Jorge Plutzky, Md, MD
Cardiovascular Disease — Payments: $973,823
Cardiovascular Disease $973,823
Robert Giugliano, Md, MD
Cardiovascular Disease — Payments: $863,219
Cardiovascular Disease $863,219